Evaluations were made on both quantitative and qualitative criteria, such as innovation, management, and global strategy.
IRVINE, Calif. (PRWEB) December 10, 2007
"Red Herring 100" winners and finalists from North America, Europe and Asia over the past three years were eligible for this award. The Red Herring editorial team "used a very competitive process to whittle down this pool of 1,800 promising companies to the 100 winners of this first-time award," said Jordy Brazier of Red Herring. "Evaluations were made on both quantitative and qualitative criteria, such as innovation, management, and global strategy." The winning companies were announced and celebrated at the Red Herring Global Award event in Seattle on Dec. 3-5.
"This important award recognizes that CoreValve is forging a new paradigm for cardiovascular medicine: replacing an aortic valve by a non-surgical transcatheter approach utilizing the Company's breakthrough ReValving(TM) System," said Jacques Seguin, M.D., Ph.D., Chairman, CEO and Founder of CoreValve. "As a result, CoreValve is seeing a rapid technology uptake by the leading European physicians due to the ease of percutaneous implantation with the ReValving(TM) System. The procedure takes about an hour and is performed generally under local anesthesia only, in a cath lab setting. While ReValving(TM) is initially focused on the highest-risk patients, there is a growing feeling among the medical community that ReValving(TM) is the procedure by which diseased aortic valves of less-sick patients will be treated in three to five years from now."
About Red Herring
Red Herring (http://www.redherring.com) is a global media company uniting the world's best high technology innovators, venture investors and business decision-makers in a variety of forums: a leading innovation-focused magazine; an online daily technology news service; technology research; and, major events for technology leaders around the globe. The magazine Red Herring provides an insider's access to the global innovation economy, featuring unparalleled insights on the emerging technologies driving the economy.
CoreValve, Inc., is headquartered in Irvine, Calif. Its proprietary ReValving(TM) System allows both percutaneous aortic valve replacement (PAVR) and transapical aortic valve replacement (TAVR) and is intended to provide an alternative to open-heart surgery. The ReValving(TM) System procedures are performed on the beating heart without cardiac assistance or rapid pacing, and may result in less trauma to the patient. This technology may also offer substantial cost-savings to the healthcare system. The catheter-based ReValving(TM) System includes a proprietary framed/self-expanding tissue heart valve that is specifically designed and engineered for transcatheter delivery. For more information about CoreValve, visit the Company's Web site at http://www.corevalve.com.
(Caution: the CoreValve ReValving(TM) System will not be available in the USA for clinical trials or for sale until further notice.)